ImmunoGen, Inc. Announces Vice President, Corporate Communications & Investor Relations, A New Post

-Company Gears Up for Anticipated 2001 Milestones-



Apr 17, 2001, 01:00 ET from ImmunoGen, Inc.

    CAMBRIDGE, Mass., April 17 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
 today announced the appointment of Donna L. LaVoie, 37, as Vice President,
 Corporate Communications & Investor Relations.  In this newly-created
 position, Ms. LaVoie is responsible for the development and execution of
 ImmunoGen's external communication.  In addition, Ms. LaVoie, a spokesperson
 for the Company, will be responsible for investor relations activities.
     "Donna brings a wealth of corporate communications and investor relations
 experience to ImmunoGen," said Mitchel Sayare, Ph.D., Chairman & CEO.  "We are
 pleased to have her on board as part of our senior management team."
     Ms. LaVoie commented, "I am extremely excited to return to my roots in
 biotechnology, where I began my career.  I have known Mitch for a long time
 and look forward to working with him and other members of the executive team
 during this growth period for the Company."
     Ms. LaVoie joins ImmunoGen with more than 10 years experience in corporate
 communications and investor relations, working in both the technology and
 biotechnology industries.  Most recently, Ms. LaVoie held the position of Vice
 President, Corporate & Strategic Marketing at Stream International, Inc.
 Prior to that she was Vice President, Investor Relations for Cambridge
 Technology Partners (Nasdaq: CATP).  Ms. LaVoie has held several other head
 communications and investor relations roles at ErgoScience Corporation;
 GenRad, Inc.; Alkermes, Inc.; and Genzyme Corporation.
     Ms. LaVoie serves on the board of the Greater Boston Salvation Army, is a
 member of The Boston Club for Senior Executive Women and the National Investor
 Relations Institute.  She holds a Bachelor of Science degree in Management
 from Lesley College and has attended several strategic marketing programs at
 The Wharton School.
     Mr. Sayare continued, "This is an exciting time for ImmunoGen as we gear
 up for several anticipated milestones for the remainder of the 2001 year:
     -- May 12 - 15 at the American Society of Clinical Oncology (ASCO)
 meeting, data from the Phase I/II human clinical study evaluating the use of
 huC242-DM1/SB-408075 for the treatment of colorectal, pancreatic and non-small
 cell lung cancer, will be presented.
     -- Initiation of two Phase I/II human clinical studies on huN901-DM1/BB-
 10901, the Company's second pipeline product, designed to treat small-cell
 lung cancer.
     -- The announcement of additional collaborations that will bring new
 targets to the Company for its product pipeline.
     -- The announcement of additional collaborations that permit other
 companies to make use of the ImmunoGen's TAP technology platform in return for
 significant near-term cash flow and royalties. These "autopilot" deals do not
 drain resources and permit all proceeds to be used to underwrite the costs of
 the Company's product pipeline."
 
     ImmunoGen develops innovative biopharmaceuticals, primarily for cancer.
 The Company has created potent tumor-activated prodrugs, consisting of drugs
 coupled to MAbs, for delivery to and destruction of cancer cells.  Its lead
 product, huC242-DM1/SB-408075 is in two Phase I/II human clinical studies for
 colorectal, pancreatic and certain non-small-cell lung cancers.  The Company
 has collaborative arrangements with GlaxoSmithKline, Genentech, British
 Biotech, Abgenix, MorphoSys, Avalon, Raven and Millennium Pharmaceuticals.
 For more information:  www.immunogen.com.
 
     This press release includes forward-looking statements based on
 management's current expectations.  Factors that could cause future results to
 differ materially from such expectations include, but are not limited to: the
 success of the Company's research strategy; the applicability of the
 discoveries made therein; the difficulties inherent in the development of
 pharmaceuticals, including uncertainties as to the timing and results of
 preclinical studies; delayed achievements of milestones; reliance on
 collaborators; uncertainty as to whether the Company's potential products will
 succeed in entering human clinical trials and uncertainty as to the results of
 such trials; uncertainty as to whether adequate reimbursement for these
 products will exist from the government, private healthcare insurers and
 third-party payors; and the uncertainties as to the extent of future
 government regulation of the pharmaceutical business.
 
     CONTACT: Donna L. LaVoie, Vice President, Corporate Communications &
 Investor Relations of ImmunoGen, Inc., 617-995-2500.
 
 

SOURCE ImmunoGen, Inc.
    CAMBRIDGE, Mass., April 17 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
 today announced the appointment of Donna L. LaVoie, 37, as Vice President,
 Corporate Communications & Investor Relations.  In this newly-created
 position, Ms. LaVoie is responsible for the development and execution of
 ImmunoGen's external communication.  In addition, Ms. LaVoie, a spokesperson
 for the Company, will be responsible for investor relations activities.
     "Donna brings a wealth of corporate communications and investor relations
 experience to ImmunoGen," said Mitchel Sayare, Ph.D., Chairman & CEO.  "We are
 pleased to have her on board as part of our senior management team."
     Ms. LaVoie commented, "I am extremely excited to return to my roots in
 biotechnology, where I began my career.  I have known Mitch for a long time
 and look forward to working with him and other members of the executive team
 during this growth period for the Company."
     Ms. LaVoie joins ImmunoGen with more than 10 years experience in corporate
 communications and investor relations, working in both the technology and
 biotechnology industries.  Most recently, Ms. LaVoie held the position of Vice
 President, Corporate & Strategic Marketing at Stream International, Inc.
 Prior to that she was Vice President, Investor Relations for Cambridge
 Technology Partners (Nasdaq: CATP).  Ms. LaVoie has held several other head
 communications and investor relations roles at ErgoScience Corporation;
 GenRad, Inc.; Alkermes, Inc.; and Genzyme Corporation.
     Ms. LaVoie serves on the board of the Greater Boston Salvation Army, is a
 member of The Boston Club for Senior Executive Women and the National Investor
 Relations Institute.  She holds a Bachelor of Science degree in Management
 from Lesley College and has attended several strategic marketing programs at
 The Wharton School.
     Mr. Sayare continued, "This is an exciting time for ImmunoGen as we gear
 up for several anticipated milestones for the remainder of the 2001 year:
     -- May 12 - 15 at the American Society of Clinical Oncology (ASCO)
 meeting, data from the Phase I/II human clinical study evaluating the use of
 huC242-DM1/SB-408075 for the treatment of colorectal, pancreatic and non-small
 cell lung cancer, will be presented.
     -- Initiation of two Phase I/II human clinical studies on huN901-DM1/BB-
 10901, the Company's second pipeline product, designed to treat small-cell
 lung cancer.
     -- The announcement of additional collaborations that will bring new
 targets to the Company for its product pipeline.
     -- The announcement of additional collaborations that permit other
 companies to make use of the ImmunoGen's TAP technology platform in return for
 significant near-term cash flow and royalties. These "autopilot" deals do not
 drain resources and permit all proceeds to be used to underwrite the costs of
 the Company's product pipeline."
 
     ImmunoGen develops innovative biopharmaceuticals, primarily for cancer.
 The Company has created potent tumor-activated prodrugs, consisting of drugs
 coupled to MAbs, for delivery to and destruction of cancer cells.  Its lead
 product, huC242-DM1/SB-408075 is in two Phase I/II human clinical studies for
 colorectal, pancreatic and certain non-small-cell lung cancers.  The Company
 has collaborative arrangements with GlaxoSmithKline, Genentech, British
 Biotech, Abgenix, MorphoSys, Avalon, Raven and Millennium Pharmaceuticals.
 For more information:  www.immunogen.com.
 
     This press release includes forward-looking statements based on
 management's current expectations.  Factors that could cause future results to
 differ materially from such expectations include, but are not limited to: the
 success of the Company's research strategy; the applicability of the
 discoveries made therein; the difficulties inherent in the development of
 pharmaceuticals, including uncertainties as to the timing and results of
 preclinical studies; delayed achievements of milestones; reliance on
 collaborators; uncertainty as to whether the Company's potential products will
 succeed in entering human clinical trials and uncertainty as to the results of
 such trials; uncertainty as to whether adequate reimbursement for these
 products will exist from the government, private healthcare insurers and
 third-party payors; and the uncertainties as to the extent of future
 government regulation of the pharmaceutical business.
 
     CONTACT: Donna L. LaVoie, Vice President, Corporate Communications &
 Investor Relations of ImmunoGen, Inc., 617-995-2500.
 
 SOURCE  ImmunoGen, Inc.